ClearPoint Neuro gets FDA clearance for SmartFrame OR

Waldemarus ClearPoint Neuro ( NASDAQ: CLPT ) said it has received FDA clearance for its SmartFrame OR Stereotactic System for neurological procedures. The company plans to conduct a limited release of the product in the first half of 2024, with a full market release in the latter half of the year. More on ClearPoint Neuro NeuroOne: A Hidden Contender Against ClearPoint In The Brain Drug Delivery Arena ClearPoint Neuro, Inc.

(CLPT) Q3 2023 Earnings Call Transcript ClearPoint Neuro, Inc. 2023 Q3 Results Earnings Call Presentation ClearPoint Neuro reports prelim Q4 & FY rev of $6.8M and $24M, higher than consensus ClearPoint Neuro GAAP EPS of $0.20 beats by $0.05, revenue of $5.76M misses by $0.97M.